Defining infection risk of bispecific antibodies for myeloma

被引：0
|
作者：
Hammond, Sarah P. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Div Infect Dis & Hematol Oncol, Boston, MA 02114 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD ADVANCES | 2024年 / 8卷 / 18期
关键词：
D O I：
10.1182/bloodadvances.2024013813
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4977 / 4978
页数：2
相关论文
共 50 条
  • [21] Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
    Zhou, Xiang
    Einsele, Hermann
    Danhof, Sophia
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
  • [22] Bispecific antibodies in multiple myeloma treatment: A journey in progress
    Cho, Shih-Feng
    Yeh, Tsung-Jang
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Bispecific antibodies for multiple myeloma: past, present and future
    Ochi, Toshiki
    Konishi, Tatsuya
    Takenaka, Katsuto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 23 - 33
  • [24] Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo
    Golay, Josee
    Regazzi, Mario
    THERAPEUTIC DRUG MONITORING, 2020, 42 (01) : 57 - 63
  • [25] Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
    Dalla Palma, Benedetta
    Marchica, Valentina
    Catarozzo, Maria Teresa
    Giuliani, Nicola
    Accardi, Fabrizio
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 11
  • [26] T-CELL BISPECIFIC ANTIBODIES SUPPRESS MULTIPLE MYELOMA
    Seckinger, A.
    Delgado, J. A.
    Moser, S.
    Moreno, L.
    Neuber, B.
    Grab, A.
    Li, J.
    Stagg, N. J.
    Johnston, J.
    Harris, M. J.
    Menzies, S. A.
    DiCara, D.
    CANCER DISCOVERY, 2017, 7 (05) : 452 - 452
  • [27] Infectious toxicities in patients treated with bispecific antibodies in multiple myeloma
    Saez, Adolfo
    Lopez-Munoz, Nieves
    Maria Sanchez-Pina, Jose
    Alonso, Rafael
    Cuellar, Clara
    Lazaro, Paula
    Jimenez Ubieto, Ana
    Calbacho, Maria
    Martinez Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S97 - S98
  • [28] T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
    Moreau, Philippe
    Touzeau, Cyrille
    BLOOD, 2022, 139 (26) : 3681 - 3687
  • [29] Efficacy of bispecific antibodies in the treatment of extramedullary disease and high risk cytogenetics in relapsed multiple myeloma: a systematic review
    Vegivinti, Charan
    Santhi, Jaison Lawrence Alexander
    Liu, Lawrence
    Hammami, M. Bakri
    Thakur, Rahul
    Ghimire, Ananta
    Poojary, Nagarathna
    Gopireddy, Murali Mohan Reddy
    Kallamvalappil, Anusha Manoj
    Jitta, Sahas Reddy
    Chintapally, Nikita
    Shah, Nishi
    Janakiram, Murali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S19 - S19
  • [30] The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
    Khanam, Razwana
    Ashruf, Omer S.
    Bin Waqar, Syed Hamza
    Shah, Zunairah
    Batool, Saba
    Mehreen, Rameesha
    Pachika, Pranali
    Roksana, Zinath
    Rehman, Mohammad Ebad Ur
    Anwer, Faiz
    ANTIBODIES, 2023, 12 (02)
12345